Home > Boards > US Listed > Biotechs >

Opko Health Inc (OPK)

Add OPK Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator dshade, DegenerateGambler, Myth, now invest
Search This Board:
Last Post: 7/29/2014 11:40:49 PM - Followers: 112 - Board type: Free - Posts Today: 0
Opko Health Initiates Phase 3 Trial of Bevasiranib for the Treatment of AMD Wednesday July 11, 8:00 am ET -Trial Designed to Compare Efficacy of Bevasiranib Administered Every 8 Weeks or 12 Weeks with Lucentis(R) Administered Every 4 Weeks- -Represents First-Ever Phase 3 Pivotal Trial of an RNAi Therapeutic- MIAMI, July 11 /PRNewswire-FirstCall/ -- Opko Health Inc. (Amex: OPK - News) today announced the initiation of the Phase 3 COBALT (Combining Bevasiranib And Lucentis Therapy) clinical trial of bevasiranib for the treatment of wet age-related macular degeneration (wet AMD.) The multi-national COBALT study is currently open and enrolling patients. The trial will include more than 330 wet AMD patients and will assess whether bevasiranib administered every 8 or 12 weeks is safe and has equivalent efficacy in preventing vision loss as Genentech's Lucentis® administered every four weeks. ADVERTISEMENT Bevasiranib is a first-in-class small interfering RNA (siRNA) drug designed to silence the genes that produce vascular endothelial growth factor (VEGF), believed to be largely responsible for the vision loss of wet AMD. Bevasiranib is the first therapy based on the Nobel Prize-winning RNA interference (RNAi) technology to advance to Phase 3 clinical trials. "This first-ever Phase 3 trial of an agent based on RNAi technology is an important milestone in this new field. We are proud of the ability demonstrated by our clinical group to have successfully moved this innovative compound through development rapidly and cost effectively," said Philip Frost, M.D., Chairman and CEO of Opko Health. "Currently patients with wet AMD undergo intravitreal injections every four weeks to achieve the vision- preserving benefits of Lucentis, so the potential ability of bevasiranib to achieve similar results while requiring less frequent injections would be an important benefit for these patients who often have limited mobility." "Bevasiranib's demonstrated safety profile, its ability to inhibit the growth of the retinal lesions associated with wet AMD and its potential for prolonged duration are a promising foundation for this pivotal trial," said Lawrence Singerman M.D., founder and Executive Secretary of the Macula Society, Clinical Professor of Ophthalmology at Case University and a Principal Investigator for the Phase 3 study. "Bevasiranib's potential to serve as a long-term maintenance therapy for wet AMD could provide important benefits to patients, and I look forward to helping to assess its utility in this groundbreaking study." "We are very pleased at the enthusiastic reception the COBALT trial has received from retinal centers around the globe," said Denis O'Shaughnessy, Ph.D., Senior Vice President of Clinical Development at Opko. "Retinal physicians are keenly aware of the burden that frequent drug injections places on elderly patients and their families, and they are eager to help test an innovative new approach that has the potential to significantly reduce that burden while preserving patients' vision." About Wet AMD Wet age-related macular degeneration is the leading cause of irreversible vision loss in the developed world and its incidence is growing rapidly. Advanced age is the main risk factor for wet AMD, and it is expected to become an increasingly common condition as the population grows older. An estimated 1.65 million Americans have wet AMD today and an estimated 11 million people worldwide will have AMD by 2013. Until recently, treatments for wet AMD were of limited efficacy. In the search for more effective treatments, researchers targeted VEGF, shown to be a key cause of the excess growth and leakiness of ocular blood vessels that result in loss of vision in these patients. Current VEGF antagonists, such as Lucentis, slow this vision loss, but require injections into the eye every four weeks, a particular issue for elderly patients who often have limited mobility. Opko Health, Inc. Announces Early Termination of Hart-Scott-Rodino Waiting Period for Proposed Purchase of Shares by Dr. Phillip Frost Thursday July 12, 8:00 am ET MIAMI July 12 /PRNewswire-FirstCall/ -- Opko Health Inc. (Amex: OPK - News) today announced that that the U.S. Department of Justice has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in connection with the potential acquisition of additional shares of Opko Health common stock by Dr. Phillip Frost, CEO and Chairman of Opko. Dr. Frost has requested clearance to purchase additional shares of Opko Health common stock, which this action by the Justice Department now makes feasible.
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
Option Chain for OPK
OPK News: Statement of Changes in Beneficial Ownership (4) 07/29/2014 05:01:07 PM
OPK News: Statement of Changes in Beneficial Ownership (4) 07/28/2014 06:57:28 AM
OPK News: Amended Statement of Changes in Beneficial Ownership (4/a) 07/24/2014 04:21:36 PM
OPK News: Statement of Changes in Beneficial Ownership (4) 07/24/2014 07:12:23 AM
OPK News: Statement of Changes in Beneficial Ownership (4) 07/23/2014 07:23:10 AM
News News Alert: Statement of Changes in Beneficial Ownership (4) 07/29/2014 05:01:07 PM
#2474  Sticky Note May 22, 2014 OPKO Completes Acquisition of Inspiro dshade 06/04/14 10:29:14 AM
#2454  Sticky Note May 9, 2014, 10:17am EDT Myth 06/03/14 02:38:24 PM
#1096  Sticky Note OPKO Point-of-Care Technology Demonstrated on Mobile Device with lbman 03/03/13 07:11:22 AM
#2754   Title: FLUIDIC CONNECTORS AND MICROFLUIDIC SYSTEMS Document Type and tomsylver 07/29/14 11:40:49 PM
#2753   CEO of OPKO picking up another Boat Load ddbulk 07/29/14 06:03:26 PM
#2752   Pretty much speaks for itself. md84 07/29/14 10:03:53 AM
#2751   I really believe that the 4K test is now invest 07/29/14 10:02:20 AM
#2750   International Journal of Nanomedicine MOD-4023 Post tomsylver 07/28/14 11:24:59 PM
#2749   True. Medical breakthroughs don't get solidified in 1 md84 07/28/14 06:39:50 PM
#2748   Frost is a very GREAT investor.. and now invest 07/28/14 12:18:04 PM
#2747   It's almost like he knows where this is md84 07/28/14 10:45:06 AM
#2746   I don't think I've ever lost on any md84 07/28/14 10:39:40 AM
#2745   yes, he's filthy rich....they tend to throw money away.. Myth 07/28/14 10:38:37 AM
#2744   Watch those lines cross and this might happen md84 07/28/14 10:37:24 AM
#2743   Love it!! As they get the word now invest 07/28/14 08:32:03 AM
#2742   CEO... BUYS MORE.... Frost knows the value here...!! now invest 07/28/14 08:29:00 AM
#2741   Digital Edition Current Issue Click here to download the current tomsylver 07/27/14 02:52:16 PM
#2740   lol...... https://www.google.com/search?q=Opko+Health%2C+Inc.%2F+executive+co Myth 07/26/14 06:13:57 PM
#2739   Please provide a link stating it was NOT now invest 07/26/14 06:09:36 PM
#2738   hit 9.22 like it was a brick wall.....guess Myth 07/26/14 01:53:03 PM
#2737   Right... OPK... Trades also with the market... unlike now invest 07/26/14 11:04:00 AM
#2736   Trans-Pacific Health Sciences Dialogue Les Funtleyder, Director of Strategic tomsylver 07/26/14 09:02:44 AM
#2735   looks like 9.22 scared this one today again..... Myth 07/25/14 04:12:31 PM
#2734   In a down market where the Dow is DegenerateGambler 07/25/14 02:08:09 PM
#2733   TOTALLY FALSE... NO PROOF PROVIDED WHATSOEVER now invest 07/25/14 11:13:54 AM
#2732   shoe me a link that it is false then.... Myth 07/25/14 09:03:01 AM
#2731   Check back.... Ah big short position all the now invest 07/25/14 07:57:44 AM
#2730   I said today they do, 4.50 ? Myth 07/24/14 06:43:31 PM
#2729   Just poor analysis!!!! Shorts have been here now invest 07/24/14 06:38:16 PM
#2728   opinions don't have links......sorry.... Myth 07/24/14 05:17:31 PM
#2727   PLEASE... SEND THE LINK THAT VERIFIES THAT DD!!!!!!! now invest 07/24/14 05:09:33 PM
#2726   shorts are controlling it..... Myth 07/24/14 02:48:48 PM
#2725   Frost bought twice this week already... He has now invest 07/24/14 02:38:23 PM
#2724   Ah... but you talked about the shorts controlling now invest 07/24/14 02:36:19 PM
#2723   anyone can look at the chart and see Myth 07/24/14 02:13:06 PM
#2722   LOL... so now it can go over $9.00 now invest 07/24/14 02:11:43 PM
#2721   My friends are buying this stock. Are you? md84 07/24/14 01:38:01 PM
#2720   Not going below 9.00 today, right now, this md84 07/24/14 01:28:38 PM
#2719   OPK 's ? Myth 07/24/14 01:24:03 PM
#2718   Credibility gone. md84 07/24/14 01:22:47 PM
#2717   that,s only a guess......fact is the shorts here Myth 07/24/14 01:19:39 PM
#2716   Breakout point reached. This should be cruising upward md84 07/24/14 01:13:57 PM
#2715   There is more people talking about OPK.. and now invest 07/24/14 12:25:44 PM
#2714   crazy spike. followed by profit taking dshade 07/24/14 10:51:09 AM
#2713   http://video.cnbc.com/gallery/?video=3000295237 Sone 07/23/14 08:21:44 PM
#2712   Oh... that day?? that hour?? THAT now invest 07/23/14 06:21:04 PM
#2711   It was actually Les Funtleyder of Bluecloud funds !! bra1loga 07/23/14 06:16:58 PM
#2710   lol....no limit on the dd.... Myth 07/23/14 05:49:22 PM
#2709   LOL.... I guess Frost knows what is happening.. now invest 07/23/14 05:45:26 PM
#2708   nice solid day here..... Myth 07/23/14 04:04:31 PM
#2707   Go! Now at 9.03 Life is good! Ag Boy 07/23/14 03:48:50 PM
#2706   taking ST waiting to add more on dip dshade 07/23/14 02:56:59 PM
#2705   another CNBC guy mentioned it during a biotech discussion. dshade 07/23/14 02:37:54 PM